SII, Gavi and BMGF collaborate for COVID-19 vaccines, SII to price per vaccine dose at Rs 225
Serum Institute of India to produce up to 100 million COVID-19 vaccine doses which will be made available to the 92 countries included in Gavi’s COVAX Advance Market Commitment
Serum Institute of India (SII) has entered into a new partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs).
The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and LMIC as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.
The funding will support at-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification. SII has set a ceiling price of $3 per dose. The arrangement also provides an option to secure additional doses if the vaccines pillar of the ACT Accelerator sees a need for it.
“In an attempt to make our fight against COVID-19 stronger and all-embracing; SII has partnered with Gavi and the Bill & Melinda Gates Foundation to advance the manufacturing and delivery of up to 100 million doses of future COVID vaccines for India and low and middle-income countries in 2021,” said Adar Poonawalla, CEO of Serum Institute of India.
“The rampant spread of the virus has rendered the entire world in an unimaginable halt of uncertainty. And to ensure maximum immunisation coverage and contain the pandemic, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures. Through this association, we seek to ramp up our constant efforts to save the lives of millions of people from this dreadful disease.” he added.
Dr Renu Swarup, Secretary, Department of Biotechnology, Government of India, shared, “India has a proven track record of manufacturing safe and cost-effective vaccines not only for India but for the world. Over the last decade, the Government of India has encouraged innovation and supported the Indian vaccine industry to manufacture high quality, affordable indigenous tools and products to benefit India and the world. We are very happy to see SII enter this global partnership to respond to the global health crisis posed by COVID-19.”
Dr Balram Bhargava, Director General of Indian Council of Medical Research (ICMR), commented, “India’s has demonstrated consistent capability in delivering on low-cost and high-quality medical research, while also maintaining technical and scientific rigour. ICMR is deeply supportive o